I am joined this morning by Chris Rowe, who is our CFO, and also Jasmin Manner, who leads our business up in the U.S. and she is based in L.A. So go those Rams, Jasmin, in the NFL this weekend. If we could tab over, please. If we could tab again. This is a transformational milestone. We are really thrilled to achieve this milestone. I know it has required some patience from our investors and a number of people, and I know for our team members, it has been a really huge journey of over 4 years. This permanent authorization really sets us up to really accelerate our strategy. We are pleased to share that we have our three SKUs authorized. It establishes us amongst a very limited group of non-U.S. businesses that operate in this highly regulated environment in the infant formula business in the U.S. It will now unlock further opportunities, not just to accelerate our business, which Jasmin will take us through, but it will also open up some adjacent segments as well, which we will talk a little bit about. If we could tab, please. I just wanted to recap a little bit about who we are in the world and what our strategy is. We have probably all seen these slides if you have been to some of our other updates. The U.S. is now a cornerstone of our global portfolio. If you look at that picture on the right there, we are a business with a prominent focus on infant formula around our Bubs brand, but we also have our CapriLac brand that is in Australia and China. That is our portfolio of brands that we will look to invest in as we move forward. Our products cover infant, toddler, and adult currently, but we do have an interest in more broadly the nutrition space. Our dominant market now, or our largest market is the U.S. We are very proud of the portfolio of markets that we have as an Australian business. We now have the U.S. business 3x bigger than our Australian business, and our China business is also bigger than Australia. We are really now a true mini multinational is what we like to say. If you move across to our strategy, a number of things here in our strategic pillars that this news from the FDA will reinforce and allow us to move forward with confidence. Firstly, our brand, it resonates with the U.S. premium natural consumer. Secondly, in terms of building a winning portfolio, our goat SKU is a product that goes exceptionally well in the U.S. We now have coverage in over 50 states and over 10,000 stores. That is a great portfolio that Jasmin will talk more about in a moment. It also, our third pillar around our farm-to-formula value chain. We have been under the scrutiny of world-class organization like the FDA. They have looked at our farm-to-formula value chain. We are proudly Australian business. We know we have got great farm-to-formula, but that has now been validated by that agency in one of the toughest markets in the world. We are very proud of that. We believe it sets us up for a great future, and so we are going to share that with you as we step through today. If we could tab, please. As you are aware, we have been building bench strength in the team. We have a great board. We have had Paul, our Chair, and Steve. Paul joined in 2023, Steve in 2019. Steve's based in Boston, but recently we've supplemented the board with two other very experienced and capable non-exec directors based offshore. We're very pleased. We've shared previously that Lori and Pascal have joined. They're both proven leaders. Having worked with them now for a few months, it's been great to benefit from their experience. Their pedigree is from very large businesses where they've worked in branded infant formula and baby. They have a very global perspective, but particularly Lori has very deep experience in the U.S. And they have worked in both large and small companies. Within their career and some of their more recent focus has been in high growth consumer businesses. They're really helping the board as we navigate the challenges and opportunities that we see ahead of us, and it's been great to welcome them onto the board. Today we'll be hearing from Jasmin shortly. She's been with the business just coming up to 12 months. She has extensive experience in the U.S. in branded baby. Likewise, she's supplemented with Annie, who's our CMO based up in L.A., doing great things, and also comes with a deep level of experience around U.S. branded consumer. Chris Rowe, our new CFO, many years in the dairy industry, but three of the last four years in the U.S. And we're fortunate to have Richard Paine join back in 2019. He's been through us on the journey. He's been a large part of the FDA submissions. Together with Kat, our GM of corporate services, that rounds out the team that focuses on the U.S. business. We've got a great team and we're ready to really move and accelerate and grow this business in the U.S. If we could tab, please. When you look at the U.S. infant formula market, it's a very large and substantial market. It's a high-value market. It's a sophisticated market. It's a competitive market. The total market's AUD 7.2 billion. The segment that we play in though is not the mass market. If you come across to the premium natural is the term that they use in the U.S., that's where we have our predominant focus. It's a newer subcategory. It's a higher value subcategory. It tends to attract consumers that are looking for better. When you say better, they could be looking for better for the environment, better for the animals, better for their baby, better for themselves, better for their family. But these are high-value consumers. They consume a lot of digital. That premium natural subsegment in infant is now AUD 842 million. It's grown over the last four years, 53.6%. It's a really interesting space for us to be, but if you come one step right, that's really our sweet spot. Predominant focus for us is our goat product. There's no goat infant formula that's manufactured in the U.S. There's ourselves and two other people that import. That's now a AUD 400 million business. It's grown from a standing start. And we now enjoy 24% market share of that high-value category. Now we're very confident of our position in this high-value sub-segment, and we look to grow from a very solid base. If we could tap, please. Brings us to the growth that we've enjoyed. Most people would be aware, we had a rapid start back in 2022, when there was an issue with one of the major infant companies. We, as an Australian business, responded. We air freighted product up into the U.S. It was a real rapid start. People like Richard Paine and Chris Lotsaris did a great job to really grow that business 52% CAGR over those ensuing years. It gives us a really solid base, and it's been great to see Chris Lotsaris grow that business, then 12 months ago, pass that over to Jasmin Manner, who joins us this morning. At this point in time, I'll hand over to Jasmin to take you through more. Thank you, Joe. When you look at this graph, we really built this foundation across three areas, and these are also the areas where we will accelerate growth in the future. First, we build a national distribution network. What does that mean? In less than one year, we expanded our distribution from around 4,000 doors into almost 12,000 stores. We are currently in all 50 states present and in all the channels that really matter in this lifestyle category. We also strengthened our inventory levels in FY26, and that was actually really important in gaining that additional distribution. Without this very stable supply chain, we could have never managed to do that. Secondly, we invested in demand generation. What is important to say here, in these founding years or in these startup years in the U.S., this demand creation was mostly generated through lower funnel investments, retail channels and shopper marketing. Then also in focusing on healthcare professionals and educating consumers through these pediatricians on the benefits of goat milk. The FDA authorization now actually gives us a greater confidence to invest in the long term, and that is what gets me, of course, super excited because we can now not only leverage the established commercial platform that we have built over the last 12 months, it really supports investment in mid and higher funnel, and therefore for the long term. We can also look at portfolio expansion, and it creates opportunities to evaluate additional supply chain efficiencies. A lot has been unlocked or at least is supported through this authorization. Let's look at distribution opportunities first. If you show the next slide, Joe. Here's what I just talked about. When I look at distribution, for me, it's not about just adding more doors, it's really making each distribution point more productive. We are currently in 17 brick-and-mortar retailers, and the biggest opportunity we saw last year was mass. We were in about 15% of all mass retail doors. Today, we are almost in 80%. We're almost covering 80% of all mass retail, and this is why we can say we are now truly a national brand. We also want to then deepen our presence within those existing accounts, and this is when I say make the distribution we have more productive. It's how can I get additional facings, better shelf positioning, and also incremental displays. All of that will then lead to higher velocities, more visibility, and at the end of the day, a higher conversion at that same retailer and that same store. Another opportunity is geographical white space. What we saw is we were underrepresented in certain states. When you look at the U.S., there are some states that are really, this saying hits as like fish where the fish is or where the fish are. There are certain states that are really higher covered by lifestyle consumers. There's California, New York, Florida, Texas, et cetera, and this is where we want to play. In those states, what is important is that you are represented at local grocery premium retailers. An example here is we launched at H-E-B in Texas, and that gives then accessibility to those Texans who are really looking for formulas like Bubs. Made a huge difference to our business. Last but not least, it's channel expansion. While we were represented in mass to a certain degree and in grocery, there was opportunity to expand in specialty stores and those natural ones, and we launched just at the beginning of this year in Sprouts Farmers Market. I think a week ago, we were now approved at Whole Foods Market to be launching there next year. I'm super excited for that. In May, we launched at Sam's Club, and the club business is for bulk buyers. As we speak, we are now rolling out at CVS, which is a drugstore channel, and really helps consumers to find the product when they are kind of in a panic mode. They just have to run around the corner and get more infant formula. All these initiatives improve really the quality of revenue, and that's what it is about, is create potential for a better mix and a higher revenue per distribution point. That's what we are focusing on. Next, please. As distribution has expanded, our marketing flywheel now helps turn accessibility into demand. While we are now accessible, now we have to get that reach those parents, convert them to buy, measure if the investment was the most productive one, and then get this flywheel running so with every turn we are becoming more effective. The idea here is that we don't have a series of one-off campaigns. It's really one story that keeps us going around. We first focus on parents that are really likely to value our differentiation, our products. Usually younger parents, let's say the Zillennials or the younger Millennials, and they are really focusing on premium ingredients, goat milk benefits, and then trusted Australian quality, and that is what we are honing in. We then want to convert this awareness into purchase. National availability means they are finding us now, they do not have to look for us really, but that means we have to work on retail activation, we are establishing user-generated content, and then very important on Amazon and Meta is really ratings, reviews, and search functions that drive awareness and then conversion in the end of the day. The third step is measurement, and that is MMM, we presented that recently. That is looking into platform analytics, Numerator for shopper data, and then incrementality that is run through our agency's proprietary analytics tool. With that, we are just improving our investment every time we are putting any post or any activation, CTV, et cetera, out there. The flywheel, in the end, builds momentum, customer acquisition becomes more efficient. That is the whole idea behind it. On the right-hand side, you will actually see that this is not just a future plan. I am so excited that in the next two, three weeks, we are actually launching our first 360 campaign, and this campaign focuses on two key points of differentiation, the benefits of goat milk, and then our Australian provenance and quality credentials. What you also can see, we call it the Go Gentle from the Get-Go. In the past, Bubs was very focused on being a solution to a digestive problem. However, our consumers use formula for about nine months. You do not want to acquire them in the third month, you want to get them from the get-go, so when the baby is born, and that is also what this campaign is about. We actually extend the lifetime of the proposition. Next, please. When we are allocating now investment toward demonstratable incremental returns, FDA authorization allows us to also activate our established presence to really scale the platform in a bigger meaning. What do I mean by this? On the one hand, we are talking about renovating the core, which is all about refreshing the brand. We have a brand refresh coming up, which will support our price and mix proposition on shelf. The new design is geared much more towards our Zillennial consumers. We have a much better highlighting of our benefits. As a functional benefit, we are introducing a high top lid with a scoop inside, which is a lot more hygienic. On the innovation side, this is all, again, about broadening our portfolio. Believe it or not, because we have our sourcing out of Australia, that gives us points of differentiation within the formula that other brands do not have, brands that come out of Europe or the U.S. We do have the ability to actually look into formula improvements or slightly modified formulas that help us extend the portfolio into the more premium segment. Also we want to extend our lifetime value of the brand by looking into adjacencies in the very near future. All of this, in the end, supports a pathway to stronger profitability, that is what I am mostly interested in, and create potential for better mix and a higher revenue per distribution point. In closing, we have a leading position in one of the fastest-growing parts of the category. We have built a national commercial platform. We have a measurable growth engine, and now we have also the regulatory certainty to invest, optimize, and scale for long-term value creation. Thank you, Jasmin. If we could tab, please. Jasmin did a great job there in talking about our core focus, what we get out of bed for each morning is to grow this amazing Bubs brand, take the great story from Australia, connect with those U.S. consumers, do it in a digital way so it is a highly effective model that drives growth and profit ultimately for our shareholders. When you look at that, another opportunity, though, that we have looked at that is definitely a secondary focus, but we have this amazing farm-to-formula supply chain. People tell us they love it. We have recently extended contracts and sourcing with our Victorian-based goat farmers. That product runs through that supply chain. We have a world-class facility in Dandenong in Melbourne, where the FDA auditors compliment us on the quality of the service, the culture of the team there. We take that product across to the U.S. We have also had other people say, "Well, could you make some product for us?" That is where we are now considering pursuing a contract manufacturing strategy. Now that we have the FDA authorization for our branded products, that is a possibility. It is something that commercially could be interesting. It is a large segment in the U.S. It would open up an opportunity to potentially participate in an additional addressable market of up to $350 billion U.S. We also, though, need to be very cognizant of the FDA regulations. We have been planning for this. It is a variant submission process that we would enter into. We did make those submissions yesterday, actually, so we are not wasting any time on that. It is an exciting opportunity. We do not have anything that we can share today that is absolutely firm, but we are on that journey, and it is a new strategy that with the milestone that we achieved on Monday, we can now put some effort into. If we could tab. Another area that we have spoken about previously is our farm-to-formula supply chain, and we have done a lot of work on this in the past 12 months. We now feel that we have mapped the market. We speak about buy, build, and rent options. As our volume grows, as we utilize the capacities that we have, and as we look at some of the tyranny of distance with supplying the U.S. from Australia, we are looking at some optionality to maybe place some asset or maybe have some partnerships in the U.S. We'd also be interested in reducing working capital, maybe reducing some of our exposure to tariffs. We have some models where we assess those different factors. One of the things the retailers tell us is they'd love us to be more responsive. For those who were around at the start of the year, we did have a very low inventory. We had to air freight product up to the U.S. We're doing a lot of work on our supply chain to try and strike the right balance between essentially operating efficiency, working capital, and then being responsive and nimble for those U.S. retailers. As I said, we've done a lot of that work. We feel ready now to action those moves when we get to those points in the business. Those decisions will be made based on hitting growth targets, profitability, and risk-return hurdles. We'll keep you apprised of any developments in those areas. Just as I'm closing on that, we do have a key focus on the U.S. where over time we may look to supplement or extend the Australian capability. But we are very committed to our Australian origin. It's part of our brand story, and so our important home market, China, rest of the world, we wouldn't necessarily see that product coming from a U.S. source. It's really about a solution primarily for the U.S. at this point. We've made great progress, and the permanency with the FDA gives us more confidence too, if we need to potentially invest capital up in the U.S. market. If we could tab, just to sort of as we start to close out now. This is a massive milestone. It's been something that's been imminent for quite a while. It's a little bit like when you go hiking and you reach a peak, and then there's another peak that you see that you need to navigate. It's been a little bit like that for some of our investors as well as our team. But we've secured permanency. It's a transformational milestone. We're very proud of that. We're very proud of the team, and our partners have helped us achieve that. Really, if you think of us more as a broader proposition, we have this amazing brand that sits in an attractive category. The authorization in the U.S. now that we have, there's definitely a moat around that. There's higher barriers for other people to achieve what we have achieved. We've done the hard yards, we've spent the money, and we now have it. We believe that allows us to build more financial momentum in our business. As Jasmin said, our brand resonates with those families in the U.S. We'll continue to invest in those high-value, premium natural families. We have a very efficient model. Jasmin spoke a lot about digital marketing. A lot of our consumers are digital natives, and so it's about being really effective with that flywheel to become known and then to have those people choose us as their partner as they're going on their feeding journey. We have a highly experienced board and leadership team. We have a very global team now. We have many, many years of infant formula and high growth in particularly the U.S. market, and China is another important market for us where we have some great skilled people like Jackie and Steve, our director, has extensive experience there as well. We feel like we can navigate a lot of the opportunities, but also some of the uncertainties that are out there in the world that we currently live in. We have a diversified portfolio. The U.S. is, as you can see in the numbers, a large part of our business, but we are diversified. I always say there's a graveyard of Australian businesses that have looked to grow outside of Australia. We have navigated that. Our business in the U.S. is 3x larger than Australia. Our China business is larger than Australia, and we have growth businesses in places like Vietnam. We are very proud of our global reach. Our Australian origin resonates with people. The final point is we are building a resilient supply chain to service those customers around the world. But for the moment, with a big priority on our U.S. families who trust Bubs to go on their feeding journey. Look, that was what we wanted to cover this morning. Adrian, I might hand back to you. I know we were hoping we may receive some questions. Yeah. No, thank you, Joe. Just to remind those that are on the call to ask a question, just put it in your Q&A and we will work through as many as we possibly can. Joe, the first one starts with a pat on the back, actually. Let me start off with that one. Always good to start that way. Congratulations on securing the FDA approval. This marks a new chapter for Bubs. May I ask, what is the estimated timeline for an additional FDA variation? Is this a requirement for private labels? Thank you. Yeah. We have secured the permanent licenses for the U.S., and the process now is a separate but related process. It is for a variant of those primary licenses that we have. I am going to be the last person that is going to make a commitment on its timeline, given what we know from the past four years at Bubs. But suffice to say, it is a different process. It is a process that we have been preparing for. We have a great team that is working on that. We have great advisors, and we have made that application just yesterday. We knew it was coming, and now we will be working diligently with our colleagues at the U.S. FDA. But it is not possible or appropriate for me to offer any view on timelines. But we will remain very engaged, and we see it as a great commercial opportunity. Thanks, Joe. Next one's just a really quick one. Have you explored supply out of New Zealand? I think I know what your answer is. We absolutely, as a global business, we look at all sources of demand. So we've been looking at different markets. The world's changing. We've looked at a market like Canada with some of the geopolitics up in North America's potentially more interesting than it was, and then even in market like the U.K., never say never. So we are scanning, we are interested in growth, but it's got to be economically rational. It's got to be where there's not huge competitors and where there's not huge geopolitical risks. Then, absolutely, on the supply side, we do have friends over in New Zealand. There are a lot of goat farmers in New Zealand. There's some great asset in New Zealand. So I would say at this point, we have nothing that we have on our immediate radar. But we look at our supply chain with a lens on can we provide quality and service and effective efficiencies to access certain markets? If you look at a market like China where there's the SAMR license, there's more SAMR licenses in New Zealand than there is in Australia, as an example. Australia has better trade terms with the U.S. We had an FTA in place before the recent tariff regime. Again, I sort of draw that reference that nothing's forever either. But if we saw great commercial opportunities in New Zealand, then my answer would be never say never. But at our core, we're very proud Australians. We love our Australian farming system. The FDA have done all the work on our Australian supply chain, and that's our core focus. Thanks, Joe. Next question. It was mentioned at the top of the call that Bubs is one of the three goat formula players in the U.S. market. All players are importers. Can you talk about direct competitors, particularly where their product is imported from, and whether they have FDA permanent authorization or are working towards that status? Yeah. We have some competitors who we respect. They do a great job. Their brands stand for things that are a little bit different to us. They do not have the amazing attributes that we have as Australians. But they do a great job. One of them is quite a lot larger than us, and they are out of the U.K. and Europe, and they do exceptionally well in the market. Yeah, we watch what they do as they watch what we do. We do not over-focus on our competitors, though, either. We run our own game. We are very happy with who we are in the world. Our brand stands for clean label. Our brand stands for the functional benefit, primarily at the moment, gentle tummies, and then this amazing of Australia. That is the game we play. It resonates with the U.S. consumers in our target set. We have done a lot of work to really understand who our consumers are, so we have got a very efficient digital marketing model to access those consumers. And they are expressing a preference to take our products on. Yeah. But it is a competitive market, and we respect our competitors, absolutely. And we wish everybody well. But we are playing our own game to win. Thank you, Joe. The next question, I will just remind the questioner that this is about the FDA authorization and governance matters are a very different forum, i.e., the AGM. I will limit the question here for your benefit, Joe. Firstly, do you anticipate the formal FDA approval versus informal approval will change the velocity of growth in the U.S.A.? Secondly, do you anticipate further capital investment is required to fully harness the U.S.A. opportunity, or will it be accelerated by operational cash flows? Yeah. We have the permanent access now, so that gives us certainty. And I think Jasmin covered a lot of those points. We now have greater confidence to invest and accelerate our strategies. As we look at renovating and innovating our products, as we look at activating our brand. But look, we are always responsible with deployment of our capital. We have a plan to run the business from within the cash flows that we generate primarily. But if there are opportunities out there, we are always looking to grow the business. In terms of some of the other things that this FDA permanency grants us. It is the things that I mentioned. It does open up the possibility, subject to further FDA approvals, to access the contract manufacturing market, as I said. And we are excited about that. But we are also very clear that it is another FDA process. Finally, our supply chain. There wouldn't have been people that would've supported us to invest in asset in the U.S. without permanency, so we have that now. That gives us a bit more optionality. We've got to look at what that would mean to our operating environment. I shared some of those variables. I think as we reach the certain triggers that we would need to see, as we look at our customer metrics around service and responsiveness, as we look at responsible deployment of capital, and as we look at our unit economics for profitability, they're the things we look at to make these decisions. As we have new news, we'll come back to the market and share it. We don't have anything further that we would be sharing today. Thanks, Joe. Couple of quick ones. How do you intend to step up sales marketing now? Targeted or broad-based? I might throw this one to Jasmin, because this is her game, particularly up in the U.S. Yep. Um- Maybe, Jasmin, you can talk about the social posts we might do with the NFL game in Melbourne and the fact that the NFL's a big game in the U.S. It's a big deal. It's something that a lot of consumers are aware of, that they're playing down in Australia. It's a little example of some social posts that would draw in on that. It really is these Zillennials, as Jasmin calls them, they move fast. They go between platforms. We weren't doing much on TikTok 12 months ago, were we, Jasmin? We chase them to where they go, and we want to be relevant, and then we want them to convert, and then have loyalty to our brand. This is Jasmin's passion. Over to you, Jasmin. Yeah. It is actually both, right? We are focused nationally. What that means, it is I call it, you go into the metropoles. This is where our consumers are. While it will be a national campaign, it is really focused on maybe 15 big cities where we know that this is where the majority of those lifestyle consumers live. That is how we will approach it and where we feel we get the best out of our buck at the end of the day. Yep. That would be the short answer to this. Okay. Thanks, Jasmin. Joe, the next question, quick one. It actually might be one that you might throw to Chris, because we have not heard from Chris yet. Comment on the U.S. path to profitability, please. Yeah. I might throw to Chris. I know he has been busting to contribute, so yep. Sure. Thanks. We have a profitable business in the U.S. now. It is structured with really good momentum in our sales. The margins are margins that we are broadly comfortable with. The distribution network is appropriate for the business. There is always opportunity in the cost structure there, but it actually works for us. The challenge becomes the rate of reinvestment that we make in marketing to keep driving it and just finding that balance between generating earnings, and reinvesting in marketing. That is really where we see it at the moment. We have got the right sort of levels of in-market inventory. So we have made that investment. We just need to keep fueling Jasmin's sales campaign at an appropriate level. Thanks, Chris. I think there's a point there. Go ahead, Joe. At a macro level, when you look at the premium natural subcategory that we spoke about earlier. It's an attractive category. It didn't exist five years ago, so it's growing rapidly. It won't continue to grow at those CAGRs forever. There's a point in time piece for us. We've been honing our model, the marketing flywheel, the branding, knowing our consumers, getting our supply chain set up. There is genuinely a level of excitement around having learnt some of the lessons and then being in that category that still has growth because it's high value, and it's effectively still settling into rhythm. When we look at that, we always make decisions about responsible deployment of capital. A variable item like the advertising or the marketing spend is something we look at all the time. Annie and Jasmin, we go through that weekly, monthly. We will be responsible with how we fund that, but there is an opportunity to really grow that brand equity and be a strong player over the next two to four years to really establish what hopefully is a very long-term position in this high-value market. I might want to add here, it is also, there are few players in the premium segment, and I see it as all of our task to grow that segment. In the end of the day, it is about educating consumers about benefits of these better-for-you brands. You asked about our direct competitors before. I do not fear them too much. I think all of the players in that premium natural segment, they are actually targeting the conventional brands. This is where we are coming from, is educating consumers about the better products, better ingredients that are offered by Bubs, and bring those new moms over to the better-for-you segment. That is the role that we are seeing in anything we do. This is a $5 billion market, so you can imagine how much potential there is to grab from these conventional brands. Thanks, Jasmin. Next question, Joe, this is probably a question for Chris again. Can you update on your inventory level in the U.S.? Is it adequate for growth? Your supply chain in Australia on dryer access and milk supply, bovine and goat? Sure. Throughout the course of the last financial year, we made quite a lot of investment in ensuring that we had the right level of inventory in market in the U.S. It is always a balance between having enough to be able to respond to demand spikes, but not over-investing. We do have quite a long physical supply chain from Australia, so having a reasonable amount of inventory in the U.S. is really important to be able to react quickly to changes in demand. Our physical supply chain, Joe talked about our facility at Dandenong in Melbourne where we do the final stage processing. That has got plenty of capacity. It is a lovely facility and has space, and we have really strong partnerships going back through drying partners and goat milk partners in Victoria as well. Pretty comfortable with the quality, capacity, and strength of our supply chain. Thanks, Chris. One for you, Joe. Any thought of partnering with bigger infant formula players for growth? We are very focused on running our own game. We are very excited about the opportunity, the rapid growth. We like that sort of fighter brand culture that the team has and while we have got the opportunities ahead of us that we have, we do not see that being part of a bigger, slower business is going to really allow us to do what we want to do. We are very proud of our culture and our rapid growth, and that is what our focus is, that is what our strategy is, and that is what we will be working on. Thanks, Joe. Next one. On the contract manufacturing opportunity, you have now lodged an FDA variant submission. Is that being driven by a specific customer or active commercial discussion? If so, what would need to happen before that can translate into meaningful revenue? Yeah, it is a typical cycle that you would see in the industry where we have people that approach us. We have great relationships. Both Chris and I have been up in the U.S. previously. Jasmin is very well known. When some of the buyers and the retailers heard Jasmin was joining, they were texting her from her, and Annie similarly. Yeah, there is a lot of discussions that we tend to have in the industry, and we are not coming from a standing start. But to actually turn the opportunity into money in the bank, anything in infant formula takes time. It is a regulated business. We are feeding infants. It can be a choice that a mom makes, sole source of nutrition for a new baby. It does take time, so a word of caution on that. But there is the fundamentals of a great opportunity. If we step it through, we know the category. We have relationships. We have a known and trusted supply chain. We have really got to secure the FDA variance. That has been lodged yesterday, so that is something we have been working on. That was obviously queuing. We did not do that between Monday and yesterday. That was something that was queuing. Now we have to have those conversations with those retailers, look at what is available, look at the timelines, look at the margin structures, look at the specs that they want, and work that through. It is something that does excite us. It is one of our areas of focus. But our bigger play is our brand. We really would be doing contract manufacturing to utilize capacity. It is not an active strategy, it is more of a strategy to utilize capacity. The free cash flow that we may generate in the future if we are successful in standing that strategy up, we would probably look to deploy some of that into accelerating our investment in brand. We think that that combination gives us what our investors want, which is enterprise value. So, the margin structure is always better on a successful branded business. They value up better in the industry. We know that. But along the journey, and in my years in FMCG, there are points in time where you work with the partners on contract manufacturing, and it can be interesting business, and that is where we see it in our strategy. We are excited, but we are cautiously moving forward, given it is a regulated category, given we need FDA approvals, given we have got to get these U.S. potential customers to know us, support us, contract with us, raise a purchase order, and then ultimately turn it into cash. There are a few steps we have got to get through. Joe, we are bumping up against time. We have got time for just one more question, just to squeeze it in. Congratulations on achieving the FDA approval. What measures do you have in place to ensure growth in the regions outside of the U.S. will not be compromised to support expansion in the U.S.? Yeah, we've got great people in our market. As an enterprise, I say we walk and chew gum. We're not a one-trick pony. We love our diversification, so we see China as an amazingly complicated and appealing market. We're doing great things up in China with CapriLac, our adult brand. We're looking at other innovations. We've got a wonderful team up in China led by a gentleman called Jackie Lin. He has about 12 people. Yeah, we have enough resource, we have capacity, we have the ability to work on multiple fronts. With that said, our strategy is quite focused. As we've said, we've got U.S., China, Australia as our home market, and then rest of the world. Yeah, it's not a big complicated business either. We're very focused, and we know where we can win, not just play, and we know where we can deliver value for our shareholders, and that's what our strategy sets out. We'll follow the strategy, we'll stick to the script. It's not just a U.S. play. We do have a broader business that we'll be looking to grow over time. Thanks, Joe. We've just gone slightly over time. For those that have asked questions we haven't got to, we will endeavor to get back to all of you. Joe, can I just pass back to you now just to wrap things up and any final remarks? Yeah, I really appreciate the interest. It's been great to have a lot of folks reach out since Monday. We appreciate the interest. Thank you for taking time today. Thank you, Jasmin. I think it might be getting a bit late in L.A. Great to have you on the team. Chris and Adrian. Yeah, we'll be available for follow-ups. Thank you for your support. Thank you all. That ends the webinar. Thank you. Enjoy your day.